Trilaciclib (Standard)

Trilaciclib (Standard) is the analytical standard of Trilaciclib (HY-101467) . This product is intended for research and analytical applications. Trilaciclib (G1T28) is an orally active CDK4/6 inhibitor with IC50 values of 1 nM and 4 nM for CDK4 and CDK6, respectively. . Trilaciclib can effectively inhibit tumor cell proliferation and reduce the hematological toxicity caused by chemotherapy. Trilaciclib attenuates apoptosis and myelosuppression induced by 5FU (HY-90006) chemotherapy[1].

Product Specifications

CAS Number

[1374743-00-6]

Target

CDK; Reference Standards

Related Pathways

Cell Cycle/DNA Damage; Others

Field of Research

Cancer

Smiles

O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C)CC6)C=C5)N=C43)CCCCC2

Molecular Formula

C24H30N8O

Molecular Weight

446.55

References & Citations

[1]Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15 (5) :783-93.